Alberto Trucchi

Sapienza University of Rome, Roma, Latium, Italy

Are you Alberto Trucchi?

Claim your profile

Publications (38)96.26 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: To assess the association between physical activity, evaluated by the Physical activity scale for elderly (PASE) questionnaire, and prostate cancer (PC) risk in a consecutive series of men undergoing prostate biopsy. From 2011 onwards, a consecutive men undergoing 12-core prostate biopsy were enrolled into a prospective database. Indications for a prostatic biopsy were a PSA value ≥ 4 ng/ml and/or a positive digital rectal examination (DRE). Body mass index (BMI) and waist circumferences were measured before the biopsy. Fasting blood samples were collected before biopsy and tested for: total PSA, glucose, HDL, trygliceridemia levels. Blood pressure was recorded. Metabolic syndrome (MetS) was defined according to the Adult Treatment panel III. PASE questionnaire was collected before the biopsy. 286 patients were enrolled with a median age and PSA of 68 (IQR 62/74) years and 6.1 ng/ml (IQR 5/8.8) respectively. Median BMI was26.4 kg/m2 (IQR: 24.6/29); median waist circumference was 102 cm (IQR: 97/108) and 75 patients (26%) presented a Metabolic syndrome. One-hundred and six patients (37%) had prostate cancer on biopsy. Patients with PC presented an higher PSA (6.7 ng/ml, IQR: 5/10 vs 5.6 ng/ml, IQR: 4.8/8; p= 0.007) and a lower LogPASE score (2.03 (1.82/2.18) vs 2.10 (1.92/2.29); p=0.005). On multivariate analysis, in addition to well-recognized risk factors such as age, PSA, prostate volume, LogPASE score was an independent risk factor for prostate cancer diagnosis (OR: 0.146, 95%CI: 0.037 - 0.577; p= 0.006). Log PASE was also an independent predictor of high-grade cancer (OR: 0.07, 95% CI: 0.006-0.764; p= 0.029). In our single centre study, an increased physical activity evaluated by the PASE questionnaire is associated with a reduced risk of PC and of high-grade prostate cancer on biopsy. Further studies should clarify the molecular pathways behind this association. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
    BJU International 04/2015; DOI:10.1111/bju.13157 · 3.13 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Transrectal prostate biopsy (TRUSbx) is the standard for the diagnosis of prostate cancer. Different bowel preparations are used for patients undergoing TRUSbx. The aim of our study was to compare two different bowel preparations for TRUSbx. From May 2012 and onwards, a selected group of men undergoing TRUS 12-core prostate biopsy were enrolled into a prospective database. Patients were randomized 1:1 to receive a rectal enema (Group A) the night before the procedure or polyethylene glycol 34.8 grams/4 liters of water the day before the procedure (Group B). A VAS scale to evaluate the patients' discomfort according to the two preparations was collected. The same antibiotic prophylaxis was performed in both groups. All complications were prospectively recorded and graded according to the Clavien Classification System (CCS). A total of 198 patients were consecutively enrolled. Mean age was 67.5 ±7.9 years, mean body mass index (BMI) was 27.1 ±4.2 Kg/m(2), mean PSA value was 9.3 ±12.6 ng/ml and the mean prostatic volume was 60.6 ±29 ml. 97 patients were enrolled in Group A and 101 in Group B. Overall post-biopsy morbidity rate was 60%. No significant differences for low-grade and high-grade complications was observed between the two groups. Patients receiving the rectal enema presented with a significantly lower VAS score (3.1 ±1.1 vs. 5.9 ±1.7; p = 0.02). Our study confirmed that a rectal enema should be considered as the standard bowel preparation in patients undergoing a TRUS biopsy; it is as effective as PEG and associated with less discomfort.
    Central European Journal of Urology 01/2015; 68(2):223-8. DOI:10.5173/ceju.2015.608
  • [Show abstract] [Hide abstract]
    ABSTRACT: PURPOSE To evaluate with MRI male patients with urinary bladder neck dysfunction, studying the anatomical aspect of bladder neck and performing voiding MR-cystourethrography. METHOD AND MATERIALS We have evaluated with MRI 21 male patients with urinary bladder neck dysfunction diagnosed with pressure-flow study. All the patients had undergone US in the month proceeding MRI and patients with BPH were excluded. The MR examinations were performed with an 1.5 Tesla superconductive magnet with the patient placed in supine position and using a phased-array body coil. The patients had urine-filled bladders and sagittal and oblique coronal TSE T2-weighted scans were performed (TR:6250ms; TE:90ms;sl.thick.:3mm; acq.time:3’38”). The oblique coronal scans were parallel to the plane of the bladder neck. 15 patients underwent also voiding MR-cystourethrography performed with T1-weighted spoiled 3D gradient-echo acquisitions on sagittal plane performed (TR:12ms; TE:2,7ms; flip-angle:40°; sl.thickness: 2mm; acq.time:12s) after the filling of bladder lumen with contrast-material-enhanced urine obtainded by the i.v administration 20 mg of furosemide followed by the i.v. administration of ¾ of the normal dose of a paramagnetic contrast agent (Magnevist, Bayer Pharma, Germany). RESULTS The entire MR examination lasted no longer than 10 minutes for each patient. We detected 18 patients with abnormality of smooth muscular structures of the bladder neck and 3 patients with bladder neck cyst. MRI allowed a perfect evaluation of the different smooth detrusor muscles of the bladder neck. In patients with the typical urinary bladder neck dysfunction, we detected the hypertrophy of posterior smooth muscular structures of bladder neck and the kyphosis of prostatic urethra. Only 6 patients were able to perform voiding MR-cystourethrography that showed the characteristic radiological features. CONCLUSION MRI with voiding MR-cystourethrography could be performed in male patients with bladder outlet obstruction in order to visualize the anatomical aspect of the bladder neck. These anatomical information are useful to determine the causes of voiding obstruction, to diagnose urinary bladder dysfunction and to establish the best therapeutic approach. CLINICAL RELEVANCE/APPLICATION MRI with voiding MR-cystourethrography could be performed to diagnose urinary bladder neck dysfunction and can substitute conventional retrograde and voiding cystourethrography
    Radiological Society of North America 2013 Scientific Assembly and Annual Meeting; 12/2013
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: To evaluate the association between metabolic syndrome (MS) and prostate cancer diagnosis and grade in patients undergoing prostate biopsy. METHODS: From 2009 onwards, a consecutive series of patients undergoing 12-core prostate biopsy for PSA value ≥4 ng/ml and/or positive digital rectal examination (DRE) were prospectively enrolled. Body mass index (BMI), waist circumferences, and blood pressure were measured before the biopsy. Blood samples were tested for: PSA, fasting glucose, triglycerides, and cholesterol HDL. MS presence was defined according to Adult Treatment Panel III criteria. RESULTS: One hundred ninety five patients were enrolled with a median age and PSA of 69 years and 5.6 ng/ml respectively. Median BMI was 27.6 kg/m(2) with 64 patients (33%) being classified as obese (BMI ≥ 30 kg/m(2) ). Eighty-six patients (44%) had MS. Eighty-three patients (43%) had cancer on biopsy; 37 (45%) with MS and 46 (55%) without (P = 0.48). PSA was independently associated with higher risk of cancer (OR 1.12/1 U PSA, P = 0.01). Out of 83 patients with prostate cancer, 42 (51%) had Gleason score 6 (12 (28.5%) presented a MS) and 41 (49%) a Gleason score ≥7 (25 (61%) presented a MS). The presence of MS was not associated with an increased risk prostate cancer (OR: 0.97, P = 0.94) but with an increased risk of Gleason ≥7 (OR: 3.82; P = 0.013). CONCLUSIONS: In our single center study, MS is associated with an increased risk of high grade Gleason score when prostate cancer is diagnosed on biopsy. However, these results should be confirmed in a larger multicenter study. Prostate © 2011 Wiley-Liss, Inc.
    The Prostate 10/2011; 71(14). DOI:10.1002/pros.21364 · 3.57 Impact Factor
  • European Urology Supplements 03/2011; 10(2):116-116. DOI:10.1016/S1569-9056(11)60308-4 · 3.37 Impact Factor
  • European Urology Supplements 03/2011; 10(2):205-205. DOI:10.1016/S1569-9056(11)60623-4 · 3.37 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To investigate the relationship between androgens and prostate cancer in patients scheduled for radical prostatectomy. Patients scheduled for open radical prostatectomy were enrolled. Blood samples were collected before prostate biopsy and 12 months later to evaluate testosterone, free testosterone, sex hormone-binding globulin (SHBG), PSA, calculated free and bioavailable testosterone. 44 patients were consecutively enrolled. 15 patients (34%) presented a Gleason score (GS) of 6, 24 patients GS 7 (54%), 1 patient (2%) GS 8, and 4 patients GS 9 (9%). Mean prostate cancer volume was 4.3 ± 5.7 cm(3). 24 patients presented a pT2 stage, 16 a pT3a stage, and 4 a pT3b stage. Positive surgical margins were detected in 12 patients (27.3%). No significant change of testosterone (4.21 ± 1.49 vs. 4.00 ± 1.48 ng/ml, p = 0.46), free testosterone (9.01 ± 3.64 vs. 8.85 ± 3.04 pg/ml, p = 0.83), SHBG (38 ± 14.39 vs. 38.5 ± 17.23 nmol/l, p = 0.71), calculated free testosterone (0.091 ± 0.13 vs. 0.067 ± 0.026, p = 0.563), and bioavailable testosterone (1.89 ± 0.722 vs. 1.88 ± 0.53, p = 0.912) was observed. In our single-center study, prostate cancer does not impact on serum androgen levels, however our results should be confirmed in a larger study.
    Urologia Internationalis 01/2011; 86(2):161-6. DOI:10.1159/000322964 · 1.15 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate the effect of tamsulosin on reducing the serum levels of prostate-specific antigen (PSA) in patients with lower urinary tract symptoms and an elevated PSA level. From June 2004 to July 2006, patients with lower urinary tract symptoms, a PSA level of >or=4 ng/mL, and a maximal flow rate of <15 mL/s received tamsulosin 0.4 mg daily for 2 months. They were then scheduled for 12-core prostate biopsy. PSA determination and a uroflow study were performed before biopsy. A total of 80 patients completed the present study. The mean patient age was 66.3 years, and the mean PSA level was 7.8 +/- 8.4 ng/mL at baseline and 7.1 +/- 9.1 ng/mL after treatment (P < .001). A total of 29 patients (36.25%) were diagnosed with prostate cancer from the biopsy findings. A significant increment in the PSA level was observed in patients with prostate cancer (6.7 versus 7.9 ng/mL; P = .002). A significant decrease in the PSA level was observed in patients with negative biopsy findings (6.9 versus 5.1 ng/mL, P = .000). Of the 38 patients with a decrease in the PSA level, 1 (2.6%) was diagnosed with prostate cancer and 37 (97.4%) with an benign prostatic hyperplasia/prostatitis. Of the 42 patients with no change in the PSA level, 28 (66.7%) had prostate cancer and 14 (33.3%) had negative findings. A change in PSA level after treatment gave a sensitivity of 96.6%, specificity of 72.5%, and diagnostic accuracy of 81% for prostate cancer. Treatment with tamsulosin seemed to reduce the PSA levels and identified patients at high risk of prostate cancer.
    Urology 08/2010; 76(2):436-41. DOI:10.1016/j.urology.2009.12.083 · 2.13 Impact Factor
  • The Journal of Urology 04/2010; 183(4). DOI:10.1016/j.juro.2010.02.1788 · 3.75 Impact Factor
  • The Journal of Urology 04/2010; 183(4). DOI:10.1016/j.juro.2010.02.1873 · 3.75 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We evaluated voiding and storage symptom evolution in patients treated with prostate photoselective vaporization by a KTP laser. Enrolled in the study were 150 consecutive patients with lower urinary tract symptoms due to benign prostatic hyperplasia and a diagnosis of bladder outlet obstruction. Patients underwent prostate photoselective vaporization with the 80 W KTP laser. Baseline parameters included prostate volume, International Prostate Symptom Score with voiding and storage symptom subscores, uroflowmetry, pressure flow study and serum prostate specific antigen. Patients were followed 1, 3, 6 and 12 months after surgery. Mean +/- SD patient age was 69.6 +/- 10 years. Mean prostate volume was 52 +/- 18 ml. Mean International Prostate Symptom Score was 22.3 +/- 4, mean maximum urine flow was 9 +/- 2.9 ml per second and mean Schäfer obstruction class was 3.6 +/- 1. An average of 190 +/- 44 kJ were delivered in a mean of 68 +/- 24 minutes with an average of 3.6 kJ/ml prostate. The mean number of fibers was 1.2 +/- 0.4. Mean catheterization time was 20 +/- 8 hours. Retrograde ejaculation was reported in 67% of patients. Prostate specific antigen was significantly decreased at 12 months (2.6 +/- 2.3 vs 0.9 +/- 0.7 ng/ml, p = 0.001). Storage symptoms decreased by 54.5%, 63.6%, 72.7% and 81.8% at 1, 3, 6 and 12 months, respectively (p <0.001). Voiding symptoms decreased 63.6%, 72.7%, 81.8% and 90.9% at 1, 3, 6 and 12 months, respectively (p <0.001). As shown by a prostate specific antigen significant decrease, proper prostate debulking may be achieved by prostate photoselective vaporization. Significant continuous improvement in storage and voiding symptoms was observed at up to 12-month followup.
    The Journal of urology 03/2010; 183(3):1098-103. DOI:10.1016/j.juro.2009.11.050 · 3.75 Impact Factor
  • The Journal of Urology 04/2009; 181(4):815-815. DOI:10.1016/S0022-5347(09)62273-4 · 3.75 Impact Factor
  • European Urology Supplements 03/2009; 8(4):266-266. DOI:10.1016/S1569-9056(09)60579-0 · 3.37 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: We evaluated the association between the number of biopsy cores revealing high grade prostatic intraepithelial neoplasia and prostate cancer in an era of extended biopsy protocol. From December 2004 to September 2007 patients referred to our clinic with a prostate specific antigen of 4 ng/ml or greater or an abnormal digital rectal examination were scheduled for transrectal ultrasound prostatic biopsy with a 12-core template. In patients with high grade prostatic intraepithelial neoplasia we proposed a second prostate specific antigen evaluation and a new 12-core biopsy after 6 months independent of prostate specific antigen. Nonparametric tests were applied for statistical analysis. We evaluated 650 patients. Of the 147 patients (22%) with high grade prostatic intraepithelial neoplasia 117 underwent a second biopsy 6 months later. Patient characteristics (age, prostate specific antigen, free-to-total prostate specific antigen ratio, prostate volume, prostate specific antigen density) were similar at initial and repeat biopsy. On second biopsy 22 patients (18.8%) presented with prostate cancer (14 with Gleason score 6, 7 with Gleason score 7 and 1 with a Gleason score 8), 75 showed isolated high grade prostatic intraepithelial neoplasia (64.2%) and 20 (17%) had chronic prostatitis. The number of cores (4 or more) involved with high grade prostatic intraepithelial neoplasia on the first biopsy was significantly associated with prostate cancer on the second biopsy (p = 0.001). Prostate specific antigen could not be used to distinguish prostate cancer from benign disease or high grade prostatic intraepithelial neoplasia. The number of cores with high grade prostatic intraepithelial neoplasia seems to be associated with the presence of cancer on second biopsy. A 6-month biopsy is recommended in patients with high grade prostatic intraepithelial neoplasia when 4 or more cores with high grade prostatic intraepithelial neoplasia are detected in the initial biopsy sample independent of prostate specific antigen.
    The Journal of urology 02/2009; 181(3):1069-74; discussion 1074-5. DOI:10.1016/j.juro.2008.10.163 · 3.75 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The development and introduction in clinical practice of finasteride, the first potent inhibitor of steroid 5-alpha-reductase that inhibits the conversion of testosterone to its active form dihydroxytestosterone, has created the possibility to prevent and treat prostatic disorder by manipulating and lowering the androgens levels in the prostate. Randomised and placebo-controlled trials have demonstrated the benefit of finasteride in men with enlarged prostatic gland owing to benign prostatic hyperplasia in terms of symptoms and urinary flow rate improvements. The Prostate Cancer Prevention Trial has clearly stated the chemopreventive properties of finasteride for prostate cancer but the necessity to provide such preventive therapy to a specific group of men with a higher risk to develop a clinically significant disease is under discussion. Finasteride is administered orally as a single daily dose. We recommend a 5 mg dose.
    Expert Opinion on Drug Metabolism &amp Toxicology 01/2009; 4(12):1561-8. DOI:10.1517/17425250802587058 · 2.93 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate the accuracy of the TRIMprob in the diagnosis of prostate neoplasm. Consecutive patients referred for prostate biopsy were prospectively enrolled. Patients had history taken, physical examination by digital rectal examination (DRE) of the prostate, assessment of total and free serum prostate-specific antigen (PSA) levels, prostate transrectal ultrasonography (TRUS), and TRIMprob test. Indications for prostate biopsy included one or more of the following conditions: total serum PSA levels of 4.0 ng/mL or more, free/total serum PSA ratio of 0.18 or less, positive results on DRE, and suspicious findings on TRUS. Twelve-core, TRUS-guided biopsies were performed with local anesthesia. A blinded investigator performed the TRIMprob test; the lowest value of the signal at 465 MHz was looked for and recorded, although data of the electromagnetic signal at 930 and 1295 MHz were also recorded. One hundred eleven patients (aged 64.9 +/- 8.1 years, mean +/- standard deviation), enrolled between November 2004 and August 2005, were analyzed. Total serum PSA level was 8.4 +/- 3.6 ng/mL, and free/total serum PSA ratio was 0.15 +/- 0.7. TRIMprob sensitivity for the diagnosis of prostate cancer was 0.86%; specificity and positive and negative predictive values were 0.60 and 0.88; accuracy was 72%. TRIMprob accuracy outperformed any other diagnostic parameter considered, including the rule of chance. The association of TRIMprob and DRE offered a sensitivity and a negative predictive value of 0.86% or greater. TRIMprob had the highest accuracy rate, among all other tests, for the diagnosis of prostate cancer. Electromagnetic detection with the TRIMprob test seems to be a promising technology and a useful additional tool for the early detection of prostate cancer.
    Urology 04/2008; 72(2):340-4. DOI:10.1016/j.urology.2007.11.058 · 2.13 Impact Factor
  • European Urology Supplements 03/2008; 7(3):224-224. DOI:10.1016/S1569-9056(08)60610-7 · 3.37 Impact Factor
  • A. Tubaro · M. Arrighi · C. De Nunzio · A. Trucchi · L. Miano
    European Urology Supplements 03/2008; 7(3):212-212. DOI:10.1016/S1569-9056(08)60561-8 · 3.37 Impact Factor
  • A. Tubaro · C. De Nunzio · A. Trucchi · L. Miano
    European Urology Supplements 04/2006; 5(2):277-277. DOI:10.1016/S1569-9056(06)61023-3 · 3.37 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Detrusor hypertrophy associated with bladder outlet obstruction can be imaged on suprapubic ultrasound, and bladder mass can be quantified from the evaluation of bladder wall thickness and bladder volume. Bladder wall hypertrophy has been found to be correlated with detrusor function. Independent studies have shown that surgical treatment of benign prostatic obstruction results in a significant decrease of bladder mass. Preliminary data suggest the possibility that medical treatment with alpha-adrenergic antagonists might also produce a reduction of bladder wall hypertrophy, although confirmation is still awaited. The development of dedicated automated ultrasound systems for the evaluation of bladder mass might result in the use of such parameters in clinical trials of treatment for benign prostatic hyperplasia and ultimately in daily urologic practice.
    Reviews in urology 02/2005; 7 Suppl 6:S35-42.

Publication Stats

368 Citations
96.26 Total Impact Points


  • 1988–2015
    • Sapienza University of Rome
      • • Department of Internal and Specialized Medicine
      • • Department of Psychology
      Roma, Latium, Italy
  • 2010
    • University of Rome Tor Vergata
      • Dipartimento di Biopatologia e Diagnostica per Immagini
      Roma, Latium, Italy
  • 1995
    • Università degli Studi dell'Aquila
      Aquila, Abruzzo, Italy